Neoantigen-Based Personalized Cancer Therapeutic Vaccines - Pipeline Insight, 2021

This “Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neoantigen-based Personalized Cancer therapeutic Vaccines Understanding

Neoantigen-based Personalized Cancer therapeutic Vaccines: Overview

Cancer vaccines use weakened or killed viruses, bacteria, or other infection-causing agents to initiate an immune response in the body. These vaccines are designed to work similarly, wherein the immune system will recognize, attack, and destroy cancer cells. They identify cancer cells as foreign, and therefore, prepare the immune system to attack the cancer cells. Cancer vaccines are one way to utilize the body's immune system to fight cancer. Neoantigens that arise from cancer-specific mutations represent another class of attractive antigens for therapeutic cancer vaccines. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently showed marked therapeutic potential in both preclinical and early-phase clinical studies. Tumor-specific antigens, also termed as neoantigens, are derived from random somatic mutations in tumor cells and not present in normal cells. Compared to those non-mutated self-antigens, neoantigens could be recognized as non-self by the host immune system and are thus attractive targets for immunotherapies with potentially increased specificity, efficacy, and safety.

"Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline landscape is provided which includes the disease overview and Neoantigen-based Personalized Cancer therapeutic Vaccines treatment guidelines. The assessment part of the report embraces, in depth Neoantigen-based Personalized Cancer therapeutic Vaccines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neoantigen-based Personalized Cancer therapeutic Vaccines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neoantigen-based Personalized Cancer therapeutic Vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Neoantigen-based Personalized Cancer therapeutic Vaccines.

Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Drugs Chapters

This segment of the Neoantigen-based Personalized Cancer therapeutic Vaccines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Drugs

FRAME-001: FRAME Therapeutics

Frame Therapeutics is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. FRAME-001 personalized vaccine is currently being evaluated in Phase II stage of development for the treatment of Non-Small Cell Lung Cancer.

GEN-009: Genocea Biosciences

GEN-009 is a neoantigen vaccine candidate in a Phase I/II a clinical trial to treat a variety of solid tumors. Unlike other neoantigen vaccines, ATLAS identifies neoantigens optimized both to patients' T cell responses and their tumors, underscoring the advantages of the technology for neoantigen selection. The Phase 1/2a clinical trial of GEN-009 consists of two parts: Part A evaluates the safety and immunogenicity of GEN-009 as monotherapy in solid tumor cancer patients with no evidence of disease. Part B evaluates the preliminary immunogenicity and efficacy of GEN-009 in combination with standard-of-care checkpoint inhibitor-based regimens in patients with advanced solid tumors.

GNOS-PV02: Geneos Therapeutics

GT-30 is a phase I/II trial of personalized vaccine, GNOS-PV02, in combination with plasmid pIL-12 and pembrolizumab in patients in second line advanced hepatocellular carcinoma (HCC). Geneos Therapeutics' GT-EPIC™ Neoantigen-Targeting Platform is based on clinically-validated DNA medicines technology exclusively licensed from Inovio Pharmaceuticals, Inc. for use in developing personalized, neoantigen-targeting immunotherapies.

Neoantigen-based Personalized Cancer therapeutic Vaccines: Therapeutic Assessment

This segment of the report provides insights about the different Neoantigen-based Personalized Cancer therapeutic Vaccines drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neoantigen-based Personalized Cancer therapeutic Vaccines

There are approx. 15+ key companies which are developing the therapies for Neoantigen-based Personalized Cancer therapeutic Vaccines. The companies which have their Neoantigen-based Personalized Cancer therapeutic Vaccines drug candidates in the most advanced stage, i.e. Phase II include, FrameTherapeutics.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neoantigen-based Personalized Cancer therapeutic Vaccines: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neoantigen-based Personalized Cancer therapeutic Vaccines therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neoantigen-based Personalized Cancer therapeutic Vaccines drugs.

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Insights

• Neoantigen-based Personalized Cancer therapeutic Vaccines Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neoantigen-based Personalized Cancer therapeutic Vaccines drugs?
• How many Neoantigen-based Personalized Cancer therapeutic Vaccines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neoantigen-based Personalized Cancer therapeutic Vaccines?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neoantigen-based Personalized Cancer therapeutic Vaccines therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neoantigen-based Personalized Cancer therapeutic Vaccines and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 3-5 business days.